Key facts
- It has raised $5.6B; the latest was PE Growth/Expansion in Oct 2024.
- Notable investors include General Catalyst, 8VC, ARCH Venture Partners, Foresite Capital, Mubadala Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Altos Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Altos Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Altos Labs
Operator of a biotechnology company intended to restore cell health and resilience. The company specializes in cellular rejuvenation programming to create a completely new approach to medicine, enabling clients to reverse disease, injury, and disabilities.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2021
- Employees
- 500
- Website
- altoslabs.com/
- Ownership
- Privately Held (backing)
Altos Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Altos Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Altos Labs in its N-PORT filings yet. We sweep new filings monthly.